Corrigendum: Morphologically distinct escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro [Front. Microbiol. 7, 437 (2016)] DOI: 10.3389/fmicb.2016.00437;Morphologically distinct escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro

Frontiers in Microbiology

Volumn 7, Issue MAR, 2016, Pages

  Mirzaei, Mohammadali Khan ^a   Haileselassie, Yeneneh ^a   Navis, Marit ^a   Cooper, Callum ^a   Sverremark Ekström, Eva ^a   Nilsson, Anders S ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Cytokines; Immune response; Multi resistant bacteria; Phage therapy; Pharmacokinetics

Indexed keywords

CYTOKINE;

ARTICLE; BACTERIOPHAGE; CELL GROWTH; CELL PROLIFERATION ASSAY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MTT ASSAY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 84964381053     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.02145     Document Type: Erratum

References (27)

1. Abedon, S. (2011). Phage therapy pharmacology: calculating phage dosing. Adv. Appl. Microbiol. 77, 1-40. doi: 10.1016/B978-0-12-387044-5.00001-7
2. Abedon, S. T. (2010). The 'nuts and bolts' of phage therapy. Curr. Pharm. Biotechnol. 11:1. doi: 10.2174/138920110790725438
3. Abedon, S. T., and Thomas-Abedon, C. (2010). Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11, 28-47. doi: 10.2174/138920110790725410
4. Adams, M. H. (1959). Bacteriophages. New York, NY: Interscience Publishers.
5. Bull, J. J., and Gill, J. J. (2014). The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front. Microbiol. 5:618. doi: 10.3389/fmicb.2014.00618
6. Bull, J. J., Vegge, C. S., Schmerer, M., Chaudhry, W. N., and Levin, B. R. (2014). Phenotypic resistance and the dynamics of bacterial escape from phage control. PLoS ONE 9:e94690. doi: 10.1371/journal.pone.0094690
7. Chan, B. K., and Abedon, S. T. (2012). Phage therapy pharmacology: phage cocktails. Adv. Appl. Microbiol. 78, 1-23. doi: 10.1016/B978-0-12-394805-2.00001-4
8. Cooper, C. J., Denyer, S. P., and Maillard, J. Y. (2014). Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. Lett. Appl. Microbiol. 58, 118-122. doi: 10.1111/lam.12161
9. Dabrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., et al. (2014). Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88, 12551-12557. doi: 10.1128/JVI.02043-14
10. Gorski, A., Miedzybrodzki, R., Borysowski, J., Dabrowska, K., Wierzbicki, P., Ohams, M., et al. (2012). Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41-71. doi: 10.1016/B978-0-12-394438-2.00002-5
11. Haileselassie, Y., Johansson, M. A., Zimmer, C. L., Bjorkander, S., Petursdottir, D. H., Dicksved, J., et al. (2013). Lactobacilli regulate Staphylococcus aureus 161:2-induced pro-inflammatory T-cell responses in vitro. PLoS ONE 8:e77893. doi: 10.1371/journal.pone.0077893
12. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapala, J., Drab, M., Jonczyk-Matysiak, E., Lecion, D., et al. (2015). Mammalian Host-Versus-Phage immune response determines phage fate in vivo. Sci. Rep. 5:14802. doi: 10.1038/srep14802
13. Khan Mirzaei, M., Eriksson, H., Kasuga, K., Haggard-Ljungquist, E., and Nilsson, A. S. (2014). Genomic, proteomic, morphological, and phylogenetic analyses of vB_EcoP_SU10, a podoviridae phage with C3 morphology. PLoS ONE 9:e116294. doi: 10.1371/journal.pone.0116294
14. Khan Mirzaei, M., and Nilsson, A. S. (2015). Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE 10:e0118557. doi: 10.1371/journal.pone.0118557
15. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., et al. (2010). Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69-86. doi: 10.2174/138920110790725401
16. Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Klopot, A., Kazmierczak, Z., et al. (2015). Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7, 4783-4799. doi: 10.3390/v7082845
17. Merabishvili, M., Pirnay, J. P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:e4944. doi: 10.1371/journal.pone.0004944
18. Miettinen, M., Matikainen, S., Vuopio-Varkila, J., Pirhonen, J., Varkila, K., Kurimoto, M., et al. (1998). Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect. Immun. 66, 6058-6062.
19. Neyen, C., and Lemaitre, B. (2015). Sensing Gram-negative bacteria: a phylogenetic perspective. Curr. Opin. Immunol. 38, 8-17. doi: 10.1016/j.coi.2015.10.007
20. Nilsson, A. S. (2014). Phage therapy-constraints and possibilities. UPS J. Med. Sci. 119, 192-198. doi: 10.3109/03009734.2014.902878
21. Ochman, H., and Selander, R. K. (1984). Standard reference strains of Escherichia coli from natural populations. J. Bacteriol. 157, 690-693.
22. Peng, L., He, Z., Chen, W., Holzman, I. R., and Lin, J. (2007). Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr. Res. 61, 37-41. doi: 10.1203/01.pdr.0000250014.92242.f3
23. R Core Team (2015). R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. Available at: https://www.R-project.org/.
24. Sarker, S. A., Mccallin, S., Barretto, C., Berger, B., Pittet, A. C., Sultana, S., et al. (2012). Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434, 222-232. doi: 10.1016/j.virol.2012.09.002
25. Skurnik, M., and Strauch, E. (2006). Phage therapy: facts and fiction. Int. J. Med. Microbiol. 296, 5-14. doi: 10.1016/j.ijmm.2005.09.002
26. Sugimoto, T., Ishikawa, Y., Yoshimoto, T., Hayashi, N., Fujimoto, J., and Nakanishi, K. (2004). Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J. Exp. Med. 199, 535-545. doi: 10.1084/jem.20031368
27. Villafane, R. (2009). Construction of phage mutants. Methods Mol. Biol. 501, 223-237. doi: 10.1007/978-1-60327-164-6_20